PENDOPHARM, a division of PHARMASCIENCE INC wins the D.W. BOLE awardPrint
On October 10, McKesson Canada hosted its 27th edition of the 2018 Distinction Awards Gala, with the theme Customizing our solutions for the future of wellness. This annual event, which recognizes the achievements of manufacturers who stand out due to their innovative spirit in delivering better health to millions of Canadians, aims to reward McKesson’s partners.
During the evening, many awards are presented to different recipients. The D.W. Bole Awardrecognizes the company that has distinguished itself through its growth, service, operational excellence and business relation with McKesson.
“We are extremely proud to announce that this year, Pendopharm has won this award. Thanks to our growing partnership with McKesson, our innovative patient support program for Glatect and our ongoing motivation, we have stood out. By innovating at all levels, both in our operational functions and in our partnerships, by remaining flexible and by focusing our efforts in protecting our patients who depend on some of our single-source products, we continue to strive for excellence and growth.”
Vice President & General Manager, Pendopharm
PENDOPHARM was established in 2010 as the specialty branded division of Pharmascience Inc., a Canadian privately-owned company and the largest pharmaceutical employer in Quebec. PENDOPHARM is focused on growing its gastroenterology portfolio with innovative products for the global market. In addition to Gastroenterology, the PENDOPHARM pipeline spans multiple therapeutic areas including Allergy, Cough & Cold, Orthopedics and Specialty Products. Strategically committed to growth, PENDOPHARM is actively engaged in licensing, partnering, developing, and marketing specialty prescription medicines as well as consumer brands.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 51st among Canada’s top 100 Research & Development (R&D) investors with over $49 million invested in 2016, Pharmascience Inc. is the 3rd largest manufacturer of over-the-counter generic drugs in the country.
Pharmascience Inc. is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. The company commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.
In 2018, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine. Pharmascience’s total donations of essential medicine is close to $70 million.